How many 8-K filings has Pharmacyte Biotech, Inc. filed?

Pharmacyte Biotech, Inc. (PMCB) has 8 8-K (Current Event Report) filings on record, spanning May 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Pharmacyte Biotech, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Pharmacyte Biotech, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Pharmacyte Biotech, Inc. (PMCB) — 8-K Filings

All 8-K filings from Pharmacyte Biotech, Inc.. Browse 8 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (8)

PharmaCyte Biotech Faces Delisting Notice — Dec 5, 2025 Risk: high
PharmaCyte Biotech, Inc. filed an 8-K on December 5, 2025, reporting a notice of delisting or failure to meet continued listing requirements as of December 1, 2
PharmaCyte Biotech Reports Director/Officer Changes & Shareholder Votes — Oct 31, 2025 Risk: medium
PharmaCyte Biotech, Inc. filed an 8-K on October 31, 2025, reporting on events as of October 30, 2025. The filing covers the departure and election of directors
PharmaCyte Biotech Enters Material Agreement, Completes Asset Deal — Sep 5, 2025 Risk: medium
PharmaCyte Biotech, Inc. announced on September 2, 2025, that it has entered into a material definitive agreement and completed an acquisition or disposition of
PharmaCyte Biotech Files 8-K on Agreements and Equity Sales — Aug 18, 2025 Risk: medium
PharmaCyte Biotech, Inc. filed an 8-K on August 18, 2025, reporting on several items including an entry into a material definitive agreement and unregistered sa
PharmaCyte Biotech Files 8-K on Security Holder Vote Matters — Apr 24, 2025 Risk: low
PharmaCyte Biotech, Inc. filed an 8-K on April 24, 2025, reporting a submission of matters to a vote of security holders. The company, incorporated in Nevada, i
PharmaCyte Biotech Files 8-K: Accountant Change — Feb 26, 2025 Risk: low
PharmaCyte Biotech, Inc. filed an 8-K on February 26, 2025, reporting changes in its certifying accountant as of February 21, 2025. The company, previously know
PharmaCyte Biotech Acquires Austrianova — May 23, 2024 Risk: medium
PharmaCyte Biotech, Inc. announced on May 20, 2024, the completion of its acquisition of privately held Austrian company, Austrianova, Inc. This strategic move
PharmaCyte Biotech 8-K: Shareholder Vote Matters Reported — May 1, 2024 Risk: low
PharmaCyte Biotech, Inc. filed an 8-K on May 1, 2024, reporting on matters submitted to a vote of security holders as of April 29, 2024. The filing details the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX